Olmesartan inhibits angiotensin II-induced migration of vascular smooth muscle cells through src and mitogen-activated protein kinase pathways

Journal of Pharmacological Sciences

Volumn 113, Issue 2, 2010, Pages 161-168

  Kyotani, Yoji ^a   Zhao, Jing ^a   Tomita, Sayuko ^a   Nakayama, Hitoshi ^a   Isosaki, Minoru ^a   Uno, Masayuki ^a   Yoshizumi, Masanori ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Angiotensin receptor blocker (ARB); Cell migration; Olmesartan

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OLMESARTAN; PROTEIN TYROSINE KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; PROTEIN TYROSINE KINASE; TETRAZOLE DERIVATIVE;

ANIMAL CELL; AORTA; ARTICLE; CELL MIGRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; NONHUMAN; RAT; VASCULAR SMOOTH MUSCLE; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; CELL CULTURE; CELL MOTION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; THORACIC AORTA;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; CELL MOVEMENT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TETRAZOLES;

EID: 77953839263     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09332FP     Document Type: Article

References (31)

1. Touyz RM. Intracellular mechanisms involved in vascular remodeling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol. 2005;90:449-455.
2. Owens GK, Reidy M. Hyperplastic growth response of vascular smooth muscle cells following induction of acute hypertensionin rats by aortic coarctation. Circ Res. 1985;57:695-705.
3. Bevan RD. An autoradiographic and pathological study of cellular proliferation in rabbit arteries correlated with anincrease in arterial pressure. Blood Vessels. 1976;13:100-128.
4. Brenner BM, Cooper ME, de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
5. Parving HH, Lehnert H, Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
6. Dahlof B, Devereux RB, Kjeldsen SE. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
7. Lithell H, Hansson L, Skoog I. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
8. McMurray JJ, Ostergren J, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
9. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
10. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97.
11. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169-2177.
12. Denes L, Jednakovits A, Hargitai J, Penzes Z, Balla A, Talosi L, et al. Pharmacologically activated migration of aortic endothelial cells is mediated through p38 SAPK. Br J Pharmacol. 2002;136:597-603.
13. Iijima K, Yoshizumi M, Hashimoto M, Akishita M, Kozaki K, Ako J, et al. Red wine polyphenols inhibit vascular smooth muscle cell migration through two distinct signaling pathways. Circulation. 2002;105:2404-2410.
14. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature. 2003;424:219-223.
15. Tsuda T, Kawahara Y, Ishida Y, Koide M, Shii K, Yokoyama M. Angiotensin II stimulates two myelin basic protein/microtubuleassociated protein 2 kinases in cultured vascular smooth muscle cells. Circ Res. 1992;71:620-630.
16. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kubler W, et al. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol. 2000;20:940-948.
17. Kyaw M, Yoshizumi M, Tsuchiya K, Kagami S, Izawa Y, Fujita Y, et al. Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase activation. Mol Pharmacol. 2004;65:832-841.
18. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.
19. Ohlstein EH, Douglas SA, Sung CP, Yue TL, Louden C, Arleth A, et al. Carvedilol, a cardiovascular drug, prevents vascularsmooth muscle cell proliferation, migration, and neointimal formation followingvascular injury. Proc Natl Acad Sci U S A. 1993;90:6189-6193.
20. Yoshizumi M, Abe J, Haendeler J, Huang Q, Berk BC. Src and Cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species. J Biol Chem. 2000;275:11706-11712.
21. Touyz RM, He G, Wu XH, Park JB, Mabrouk ME, Schiffrin EL. Src is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension. 2001;38:56-64.
22. Takahashi T, Kawahara Y, Taniguchi T, Yokoyama M. Tyrosine phosphorylation and association of p130Cas and c-Crk II by ANG II in vascular smooth muscle cells. Am J Physiol. 1998;274:H1059-H1065.
23. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995;377:539-544.
24. Ishida T, Ishida M, Suero J, Takahashi M, Berk BC. Agoniststimulated cytoskeletal reorganization and signal transduction at focal adhesions in vascular smooth muscle cells require c-Src. J Clin Investig. 1999;103:789-797.
25. Ishida M, Ishida T, Thomas SM, Berk BC. Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. Circ Res. 1998;82:7-12.
26. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369:1431-1439.
27. Kondo J, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, et al. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J. 2003;146:E20.
28. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
30. Clark MA, Guillaume G, Pierre-Louis HC. Angiotensin II induces proliferation of cultured rat astrocytes through c-Jun Nterminal kinase. Brain Res Bull. 2008;75:101-106.
31. Zhang A, Ding G, Huang S, Wu Y, Pan X, Guan X, et al. c-Jun NH2-terminal kinase mediation of angiotensin II-induced proliferation of human mesangial cells. Am J Physiol Renal Physiol. 2005;288:F1118-F1124.